Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24250256 | 1.00 | DPP4 (1.00) | DPP4CHRM1 | |
| SCHEMBL20248003 | 0.92 | DPP4 (0.86) | DPP4 | |
| SCHEMBL3971994 | 0.91 | DPP4 (0.83) | DPP4 | |
| SCHEMBL3971991 | 0.91 | DPP4 (0.83) | DPP4 | |
| SCHEMBL3964977 | 0.91 | DPP4 (0.83) | DPP4 | |
| SCHEMBL3964982 | 0.91 | DPP4 (0.83) | DPP4 | |
| SCHEMBL24311071 | 0.90 | DPP4 (0.82) | DPP4CHRM1 | |
| SCHEMBL3967057 | 0.89 | DPP4 (0.80) | DPP4 | |
| SCHEMBL3967050 | 0.89 | DPP4 (0.80) | DPP4 | |
| SCHEMBL3971324 | 0.88 | DPP4 (0.78) | DPP4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3305787-B1 | XANTHINE DERIVATIVE | JIANGSU TASLY DIYI PHARMACEUTICAL CO LTD (CN) | 2022-02-16 | — | — | EP | disclosed |
| CN-107709324-B | Xanthine derivatives | 江苏天士力帝益药业有限公司 | 2021-06-08 | — | — | CN | disclosed |
| CN-106188058-B | Xanthine derivatives | 江苏天士力帝益药业有限公司 | 2020-11-06 | — | — | CN | disclosed |
| US-10358449-B2 | Xanthine derivative | Jiangsu Tasly Diyi Pharmaceutical Co, LTD. (CN) | 2019-07-23 | — | — | US | disclosed |
| US-20180162860-A1 | XANTHINE DERIVATIVE | JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD. (CN) | 2018-06-14 | — | — | US | disclosed |
| US-20180162860-A1 | XANTHINE DERIVATIVE | JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD. (CN) | 2018-06-14 | — | — | US | disclosed |
| EP-3305787-A1 | XANTHINE DERIVATIVE | Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (CN) | 2018-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162860-A1 | XANTHINE DERIVATIVE | XDH, CXCR1, CBR1 | DPP4 1294/4885CHRM1 56/4885 |
| US-10358449-B2 | Xanthine derivative | XDH, CXCR1, CBR1 | DPP4 1294/4885CHRM1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.